Grace Therapeutics, Inc. (GRCE)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Between 2026-06-21 and 2026-09-19, public records show 2 signals for Grace Therapeutics, Inc.. Most notable: 2026-09-09: Kohli Prashant (director) bought $214k of stock; 2026-08-06: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-09-19 from public records.
Signals, last 12 months
- Insider purchaseKohli Prashant (director) bought $214k of stock
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-09 | Opaleye Management Inc. | ten percent owner | P | 5,836 | 2.09 | $12,197 |
| 2026-09-09 | Kohli Prashant | director | P | 100,000 | 2.14 | $214,000 |
| 2026-09-08 | Opaleye Management Inc. | ten percent owner | P | 9,393 | 2.1 | $19,699 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.